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Calcium channel activity in vascular smooth muscle cells
is a critical component during vascular calcification and
formation of matrix vesicles. Here, we examined whether the
blockade of L-type calcium channels inhibits these functions.
Bovine vascular smooth muscle cells or rat aorta organ
cultures were incubated in media known to promote
calcification and treated with the L-type calcium
channel inhibitors verapamil, nifedipine, or nimodipine.
The phenylalkylamine, verapamil, significantly decreased
calcification of the vascular smooth muscle cells and
rat aorta, in a dose-dependent manner, whereas the
dihydropyridines, nifedipine and nimodipine, had no effect.
Furthermore, verapamil, but not nifedipine, significantly
decreased the alkaline phosphatase activity of bovine
vascular smooth muscle cells. Verapamil pretreatment of
the cells also inhibited matrix vesicle alkaline phosphatase
activity and reduced the ability of these matrix vesicles to
subsequently calcify on a type I collagen extracellular matrix
scaffold. As L-type channels are blocked by verapamil and
dihydropyridines, we suggest that verapamil inhibits vascular
smooth muscle mineralization and matrix vesicle activity by
mechanisms other than the simple blockade of this calcium
channel activity.
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Vascular calcification is a prominent finding in aging,
diabetes, chronic kidney disease, and inflammatory
diseases. The pathophysiology of vascular calcification is
complex but appears to parallel the mechanism of normal
mineralization, in which osteoblast/chondrocytes (or osteo-
blast-like vascular smooth muscle cells) produce cell
outpockets containing calcium and phosphorus called
matrix vesicles (MVs). On the basis of the phospholipid
content, high alkaline phosphatase activity, and the
presence of specific transporters and receptors, MVs are
believed to originate from cells by ‘pinching off ’ from the
cell membrane.1,2 These MVs bind to extracellular matrix
proteins to initiate mineralization. MVs produced by
mineralizing chondrocytes and calcifying vascular smooth
muscle cells (VSMCs), unlike non-mineralizing MVs, have
high alkaline phosphatase activity and contain annexins II, V,
and VI, and actively take up Ca2þ .3–5 The importance of the
calcium influx is further shown by our studies demonstrating
that the blockade of annexin calcium channel activity by
K201 significantly decreased ALP activity and reduced the
ability of the MVs to subsequently calcify on collagen.5
Intracellular Ca2þ is tightly regulated in vascular smooth
muscle cells and calcium channels are the major route by
which Ca2þ enters the smooth muscle cells.6 Differentiated
VSMCs express a large repertoire of ion channels, including
voltage-dependent L-type Ca2þ channels.7 These channels
are critical in regulating VSMC differentiation, function,
and synthesis of matrix components. L-type calcium
channel blockers are a widely used group of agents for
hypertension and cardiovascular disease and include pheny-
lalkylamines (verapamil) and dihydropyridines (nifedipine
and nimodipine), each of which have unique structures and
differing binding sites on the channel. We have previously
found that K201, an inhibitor of the annexin calcium
channel, inhibited VSMC calcification. However, annexins
and L-type calcium channels also have effects beyond changes
in calcium influx. The objective of this study is to determine
whether the prevention of intracellular calcium increase by
blockade of L-type calcium channels may also inhibit
calcification and MV formation and activity in VSMCs,
which would provide insights into the pathogenesis of
calcification.
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RESULTS
Intracellular calcium [Ca]i changes in BVSMCs treated with
verapamil or nifedipine
To confirm the presence of L-type calcium channels in
control or calcified bovine vascular smooth muscle cells
(BVSMCs), western blot was performed using anti L-type
calcium channel (a1c) antibody (a gift from Dr Randall
Duncan, University of Delaware) to determine the expression
of L-type calcium channels. As shown in Figure 1a, there is
expression of L-type calcium channel in BVSMCs. However,
there is no significant difference in the expression of L-type
calcium channel between control and calcified BVSMCs. To
determine whether L-type calcium channel blockers can
prevent the increase in [Ca]i, BVSMCs were pretreated with
or without the phenylalkylamine L-type calcium channel
blocker verapamil (10 mmol/l) or the dihydropyridine L-type
calcium channel blocker nifedipine (10 mmol/l) before
loading with fura 4-AM. Cells were depolarized by
80mmol/l Kþ (high K) buffer to induce increase in [Ca]i.
Intracellular calcium changes were examined by confocal
microscopy and quantified (Figure 1b). There was an increase
in [Ca]i in control BVSMCs in response to depolarization
with high K (Figure 1b). However, both verapamil and
nifedipine blocked the increase in [Ca]i.
The role of L-type calcium channel blockade in alkaline
phosphatase and calcification in BVSMCs
To determine the role of L-type calcium channels in
calcification and alkaline phosphatase (ALP) activity in
BVSMCs, cells were incubated in DMEM in calcification
media (with 10mmol/l beta-glycerophosphate) in the pre-
sence or absence of various concentrations of the L-type
calcium channel blockers verapamil (phenylalkylamine),
nifedipine, or nimodipine (both dihydropyridine) for 7 days.
Calcification was determined by HCL extraction. As shown in
Figure 2, verapamil significantly decreased calcification in
BVSMCs in a dose-dependent manner. However, neither
nifedipine nor nimodipine had an effect on calcification in
BVSMCs (Figure 2). Furthermore, verapamil, but not
nifedipine, significantly decreased alkaline phosphatase
activity in BVSMCs (Figure 3). These results suggest that
only the phenylalkylamine/L-type calcium channel blocker
verapamil prevented calcification and decreased ALP activity
in BVSMCs.
Ex vivo effect of L-type calcium channel blockade on rat aorta
calcification
We next investigated whether the observed effect of L-type
calcium channel blockade on in vitro BVSMC calcification
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Figure 1 | The expression of L-type calcium channels and
intracellular calcium [Ca]i changes in BVSMCs treated with
verapamil or nifedipine. (a) To determine the expression of
L-type calcium channels in BVSMCs, cell lysates were isolated from
control or calcified BVSMCs and western blot performed using anti
L-type calcium channel (a1c subunit). (b) To determine whether L-
type calcium channel blockade can prevent the increase in [Ca]i,
BVSMCs were pretreated with or without phenylalkylamine L-type
calcium channel blocker verapamil or dihydropyridine L-type
calcium channel blocker nifedipine before loading with fura 4-AM.
Cells were depolarized by 80mmol/l Kþ (high K) buffer to induce
increase in [Ca]i. Intracellular calcium changes were examined by
confocal microscopy and quantified. (c) Quantitative analysis of
changes in [Ca]i in BVSMCs treated with verapamil or nifedipine.
Data are shown as mean±s.d. from three separate experiments
(total n¼ 9). *Po0.05, high K vs normal Ca2þ buffer. BVSMCs, bovine
vascular smooth muscle cells.
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Figure 2 |The effect of L-type calcium channel blockade on
calcification in BVSMCs. BVSMCs were incubated in calcification
media (with 10mmol/l b-glycerophosphate) in the presence or
absence of various concentrations of the L-type calcium channel
blockers verapamil (phenylalkylamine), nifedipine, or nimodipine
(dihydropyridines) for 7 days. Calcification was determined by HCL
extraction. The results showed that verapamil dose-dependently
decreased calcification in BVSMCs. Neither nifedipine nor nimodipine
had an effect in calcification in BVSMCs. Data are shown
as mean±s.d. from four separate experiments (total n¼ 12).
*Po0.05 vs no blocker, #Po0.05, high dose vs 1 mmol/l blocker.
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could be reproduced ex vivo using an organ culture system.
The aorta organ cultures have the benefit of including
endothelial cells and vascular smooth muscle cells as well as
other cell types, which may all contribute to aorta calcifica-
tion. Aortas were calcified in an organ culture system
by the addition of calf intestinal alkaline phosphatase and
sodium phosphate to DMEM without serum (calcification
media) in the presence or absence of increasing concentra-
tions of verapamil or nifedipine. Viability of organ
cultures at 7 days was assessed by the measurement of lactic
dehydrogenase secretion into the medium to determine
maximal tolerable concentration. The results showed
that verapamil dose-dependently decreased calcium
content in rat aorta ring cultures, whereas nifedipine had
little effect on aorta calcification (Figure 4). These
results suggest that, similar to an in vitro cell study, verapamil
but not nifedipine significantly inhibited rat aorta
calcification ex vivo.
The effects of ryanodine receptor antagonists and activators
on calcification in BVSMCs
Studies in rabbit skeletal muscle cells have reported that
verapamil, but not dihydropyridines, can also directly bind to
the ryanodine receptor to inhibit ryanodine receptor-
mediated release of calcium from the sarcoplasmic reticu-
lum.8 To determine whether ryanodine receptors are involved
in the inhibition of calcification by verapamil in BVSMCs,
cells were treated with calcification media in the presence or
absence of various concentrations of the ryanodine receptor
antagonists dantrolene and ryanodine, as well as ryanodine
receptor activators caffeine and 4-chloro-m-cresol (CMC) for
7 days and the calcification determined. Our results showed
that blocking or activating ryanodine receptors had no effect
on calcification in BVSMCs (data not shown). These results
suggest that ryanodine receptors are not involved in
calcification.
Verapamil inhibited alkaline phosphatase activity in matrix
vesicles (MVs) from calcified BVSMCs and reduced the ability
of MVs to calcify collagen
We then asked if verapamil had similar effects to K201, an
annexin calcium channel inhibitor, by determining whether
there was an additive effect of verapamil with K201 on
BVMSC calcification. There was no additive inhibitory
effect on calcification (1.10±0.15 mmol/mg, verapamil;
1.21±0.20 mmol/mg, verapamilþK210), suggesting similar
mechanisms of action. We have previously shown that K201
inhibited the activity of matrix vesicles in BVSMCs,5 and
therefore we determined whether verapamil also reduced MV
activity. BVSMCs were incubated in DMEM in calcification
media (with 10mmol/l b-glycerophosphate) or non-calcify-
ing media (no b-glycerophosphate) for 7 days in the presence
or absence of verapamil, and MVs isolated by collagenase
digestion from these cell cultures.5 The addition of verapamil
significantly decreased ALP activity in MVs isolated from
calcified BVSMCs (calcified¼ 4165±273 U/g protein;
calcifiedþ verapamil¼ 2460±97U/g protein, Po0.01), but
had no effect on ALP activity in MVs from control (non-
calcified) BVSMCs (control¼ 607±231 U/g protein; con-
trolþY-27632¼ 804±347 U/g protein) (Figure 5).
To determine the role of verapamil in MV calcification on
the extracellular matrix, BVSMCs were incubated in calcify-
ing or non-calcifying conditions in the presence or absence of
verapamil for 7 days and MVs were isolated, placed on type I
collagen-coated dishes, and incubated with calcification
media (10mmol/l b-glycerophosphate) but no cells for
3 days for the MV—collagen calcification assay.5 MVs
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Figure 3 | The effect of L-type calcium channel blockade on
alkaline phosphatase (ALP) activity in BVSMCs. BVSMCs were
treated with control (no b-glycerophosphate) or calcification
media (with b-glycerophosphate calcified) in the presence of
10mmol/l of verapamil or nifedipine for 7 days and alkaline
phosphatase activity was determined by colorimetric assay. The
results showed that verapamil, but not nifedipine, significantly
decreased ALP activity in BVSMCs. Data are shown as mean±s.d.
from four separate experiments (n¼ 12). *Po0.01, control vs
calcified, #Po0.05, verapamil vs nifedipine, calcified.
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Figure 4 | Ex vivo effect of L-type calcium channel blockade
on rat aorta calcification. Rat aortic rings were incubated
immediately after harvest in DMEM with 7.5 units/ml of calf
intestinal alkaline phosphatase and 3.8mmol/l sodium phosphate
(calcification medium) in the presence or absence of verapamil or
nifedipine (0, 10 or 20 mmol/l) for 7 days. The calcium content was
determined by HCL extraction and normalized by tissue weight.
The results showed that verapamil dose-dependently inhibited rat
aortic calcification, whereas nifedipine had no effect. Data are
shown as mean±s.d. (n¼ 3 from a total of three rats). *Po0.01 vs
no blocker, #Po0.05, 20 mmol/l vs 10 mmol/l blocker.
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isolated from BVSMCs incubated with verapamil significantly
impaired the ability of MVs to subsequently calcify collagen
(Figure 6, *Po0.001, calcified vs control; #Po0.01, verapamil
vs no verapamil). However, when verapamil was added to
calcifying MVs incubated with type I collagen after the MVs
were already formed, verapamil did not inhibit calcification
(6.46±0.85 mmol/mg, no verapamil; 6.26±1.20 mmol/mg,
verapamil). Furthermore, MV isolated from calcifying
BVSMCs did not express L-type calcium channels by western
blot (data not shown) despite the expression in BVSMCs
(Figure 1). These results showed that verapamil, when added
during mineralization, decreased MV alkaline phosphatase
activity and inhibited the ability of matrix vesicles to
mineralize in BVSMCs. However, the addition of verapamil
to existing MVs had no effect. These data suggest that the
phenylalkylamine L-type calcium channel blocker verapamil
regulates BVSMC MV formation and their subsequent ability
to calcify.
DISCUSSION
In this study, we have shown that bovine vascular smooth
muscle cells express L-type calcium channels and that both
the phenylalkylamine L-type calcium channel blocker vera-
pamil and the dihydropyridine L-type calcium channel
blocker nifedipine can block an increase in intracellular
calcium induced by depolarization with 80mmol/l Kþ
solution. Verapamil also dose-dependently decreased calcifi-
cation and alkaline phosphatase activity in BVSMCs, whereas
nifedipine and nimodipine had no effect on calcification or
alkaline phosphatase activity. Furthermore, ex vivo studies
showed that verapamil, but not nifedipine, inhibited rat aorta
calcification in a dose-dependent manner in the organ
culture system. Verapamil also significantly decreased alkaline
phosphatase activity in matrix vesicles isolated from calcify-
ing BVSMCs and impaired the ability of MVs to subsequently
calcify on collagen. The failure of the dihydropyridine L-type
calcium channel blockers to inhibit calcification, despite
similar changes in intracellular calcium, suggests that there
are unique properties of verapamil beyond the simple
blockade of the L-type calcium channel that is responsible
for its inhibitory effect on VSMC calcification.
L-type Ca2þ channel blockers are efficacious and widely
used drugs in the treatment of hypertension and cardiovas-
cular disease.9 L-type calcium channel blockers may affect
many calcium-dependent events in the formation of athero-
sclerosis, such as the localized accumulation of collagen,
elastin, and calcium, together with monocyte infiltration and
smooth muscle proliferation and migration.10 In a human
study that evaluated calcification by CT imaging, nifedipine,
but not amlodipine, plus a diuretic showed significant
inhibition of coronary calcium progression over a 3-year
period.11 In rats, amlodipine prevented aortic medial
elastocalcinosis, pulse wave velocity, and pulse pressure
induced in a calcification model induced by inactivation of
the matrix Gal protein with vitamin K.12 An early study by
Schraven et al.13 showed that verapamil inhibited vitamin
D3-induced aorta calcification by 15% in rats. However, our
ex vivo and in vitro studies clearly indicated that only
verapamil and not nifedipine had an inhibitory effect on
VSMC calcification. In an in vitro study, amlodipine also had
no effect on calcification in primary cultures of rat VSMCs
incubated with high calcium media,14 similar to our findings
with other dihydropyridines. The differences in the effect of
dihydropyridines given in vivo compared with in vitro or
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Figure 6 | The effect of verapamil on matrix vesicle collagen
calcification. BVSMCs were incubated in control
(no b-glycerophosphate) or calcification media (with 10mmol/l
b-glycerophosphate, calcified) in the presence or absence of
10mmol/l verapamil for 7 days. MVs were isolated by collagenase
digestion and added to type I collagen-coated coverslips in
the presence of calcification media (with 10mmol/l
b-glycerophosphate) and incubated for 3 days. The calcium
content was determined by HCL extraction. Verapamil
significantly decreased the ability of MV to subsequently calcify
on type I collagen. Data are shown as mean±s.d. from three
separate experiments (n¼ 9). *Po0.01, calcified vs control, same
treatment; #Po0.05, verapamil vs no verapamil, calcified or
control.
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Figure 5 | The effect of verapamil on matrix vesicle (MV) activity.
BVSMCs were incubated in control (no b-glycerophosphate) or
calcification media (with 10mmol/l b-glycerophosphate, calcified)
in the presence or absence of 10 mmol/l verapamil for 7 days.
MVs were isolated by collagenase digestion and alkaline phosphatase
activity was determined and normalized by total MV protein content.
Verapamil significantly decreased MV alkaline phosphatase activity
from calcified BVSMCs but had no effect on control BVSMCs. Data
are shown as mean±s.d. from three separate experiments (n¼ 9).
*Po0.05, calcified vs control, same treatment; #Po0.05, verapamil vs
no verapamil.
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ex vivo may be attributed to the presence of an endothelium
in vivo or other systemic factors, which may itself affect
vascular smooth muscle cells. In contrast, isolated VSMC
cultures provide a mechanistic insight into the pathogenesis
of medial calcification that can occur despite normal
endothelium.15,16
Differentiated VSMCs express various ion channels,
including voltage-dependent L-type calcium channels.17,18
Most ion channels are not expressed in the multipotential
cells that give rise to VSMCs, but rather appear during
differentiation/maturation. Calcium channels are particularly
important in VSMCs and are responsible for regulating
VSMC contractility, proliferation, and cell death.19 The
expression of L-type Ca2þ channel a1 subunits, a functional
Ca2þ channel, is highly coordinated with expression of the
smooth muscle-specific proteins required for specialized
smooth muscle cell functions.7 Our data confirm the
presence of these channels in BVSMCs, but despite similar
effects on intracellular calcium influx, only verapamil but not
dihydropyridines inhibited calcification and the differentia-
tion marker alkaline phosphatase activity. These classes of
calcium channel blockers are known to have physiological
differences, in part because of differences in their binding
sites of the L-type channel. Our findings that verapamil, but
not nifedipine or nimodipine, inhibited calcification in
BVSMCs despite similar effects on intracellular calcium
influx suggest that additional mechanisms are involved.
To explore the mechanism by which verapamil, but not
dihydropyridines, inhibits alkaline phosphatase and calcifica-
tion in BVSMCs, we examined the role of the ryanodine
receptor. Ryanodine receptors are intracellular Ca2þ chan-
nels that mediate the release of calcium from the sarcoplas-
mic reticulum, an essential step in muscle contraction.20 In
skeletal muscle, it is thought that activation occurs through a
physical coupling to the L-type calcium channels. Ryanodine
receptors in the sarcoplasmic reticulum control myocardial
calcium homeostasis, which in turn regulates myocardial
function,21 and inhibition of ryanodine receptor activity was
associated with myocardial calcification in the rat.22 Vera-
pamil can directly bind to the ryanodine receptor channel of
sarcoplasmic reticulum and inhibit the calcium release in
rabbit skeletal muscle, whereas dyhydropyridines do not.8
However, our results showed that neither the inhibition nor
the activation of ryanodine receptors had an effect on
calcification in BVSMCs, showing that our observed effect of
verapamil on calcification is not mediated by the inhibition
of the ryanodine receptor.
To further examine the observed differences between
verapamil and dihydropyridines, we examined the effect of
verapamil on the formation and activity of MVs, the
membrane outpockets that are believed to be the initiator
of extracellular matrix calcification. We found that verapamil
decreased MV activity and its ability to calcify on type I
collagen. However, when verapamil was added to MVs
isolated from calcifying cells after MV formation from cells
not exposed to verapamil, there was no effect. In addition,
MVs did not express L-type calcium channels. MVs are
known to arise from cell membranes based on their lipid
composition and expression of various proteins and
receptors commonly expressed in cell membranes, including
annexins.23 We have previously shown that annexin calcium
channel activity is critical for calcification in BVSMCs and
that the blockade of annexin calcium channel activity by
K201 also inhibited matrix vesicle activity and its ability to
subsequently calcify on collagen.5 Annexins also affect
membrane structure and function, interacting with the
hydrocarbon chains of membrane lipids. This results in
alterations of phospholipid membrane domains with resul-
tant diverse effects.24 We have previously shown that K201,
which alters annexin conformation enabling calcium entry
into the cells, had similar effects as verapamil on calcification,
alkaline phosphatase activity, and MV activity. Furthermore,
there was also no additive effect of verapamil and K201 on
BVSMC calcification, suggesting similar mechanisms of
action. Verapamil, but not dihydropyridines, bind to multi-
drug-resistant membrane vesicles,25 and this effect is felt
secondary to the specific effect of verapamil on membrane
lipid bilayers,26 which subsequently affects membrane
potential.27 Thus, incubation of BVSMCs with verapamil
may alter membrane lipid dynamics and thereby alter MV
formation and subsequent BVSMC calcification, a hypothesis
supported by our findings that verapamil added to MV after
the formation had no effect.
In conclusion, our results showed that although L-type
calcium channels are present in BVSMCs, only the pheny-
lalkylamine L-type calcium channel blocker verapamil is
involved in VSMC mineralization and MV activity and
function. The failure of dihydropyridine L-type calcium
channel blockers to exert a similar effect suggests that there
are unique properties of verapamil beyond the simple
blockade of the L-type calcium channel that is responsible
for its inhibitory effect on VSMC calcification and matrix
vesicle activity. Our data suggest that these effects are likely
because of the alterations in the membrane structure, similar
to the proposed mechanism by which annexins may be
involved in calcification. However, further studies are
required to confirm this.
MATERIALS AND METHODS
Cell culture
Bovine vascular smooth muscle cells (BVSMCs) were isolated from
the descending thoracic aorta by the explant method as previously
described.28 The BVSMCs were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM; Sigma, St Louis, MO, USA), with 10%
FBS until confluent, at which time they were replated for specific
experiments. Only cells between passages 2–8 were used in the
experiments. To induce calcification, BVSMCs were treated with
10mmol/l b-glycerophosphate, 107mol/l insulin, and 50 mg/ml
ascorbic acid in the presence of 15% serum.28 Control or non-
calcifying BVSMCs were cultured in identical conditions, but
without the b-glycerophosphate. In some experiments, BVSMCs
were also treated with various concentrations of calcium channel
blockers: verapamil, nifedipine, diltiazem (Calbiochem, CA, USA).
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BVSMCs were also treated with the ryanodine receptor antagonists
dantrolene and ryanodine, and ryanodine receptor activator
4-chloro-M-cresol (CMC) (Calbiochem, CA, USA).
Intracellular Ca2þ measurement
Cells were loaded with 5 mmol/l fura 4-AM (Molecular Probes,
Eugene, OR, USA), a fluorescent calcium indicator, in Hank’s
balanced saline solution (HBSS) for 30min at 37 1C. Cells were
rinsed and incubated for an additional 30min with HBSS alone to
allow for complete de-esterification of the fluorescent probe.
Intracellular calcium changes were examined by confocal micro-
scopy and quantified using Metamorph software.
Western blotting
Western blotting was performed as previously described.28 The blots
were incubated overnight at 4 1C with antibody against the L-type
calcium channel (a1c subunit, 1:1000, a gift from Dr Randall
Duncan, University of Delaware), followed by incubation with
peroxidase-conjugated secondary antibody (1:5000 dilution), and
immunodetection with the Enhanced Chemiluminescence Kit
(Amersham, Piscataway, NJ, USA). The band intensity was analyzed
by scanning densitometry (Quantity One, Bio-Rad, Richmond,
CA, USA).
Matrix vesicle (MV) isolation
MVs were isolated by collagenase digestion as previously described.5
Cells were incubated with crude collagenase (500U/ml, type IA,
Sigma) in a solution of 0.25mol/l sucrose, 0.12mol/l NaCl,
0.01mol/l KCL, and 0.02mol/l Tris buffer, pH 7.45, at 37 1C for
3 h. The digests were centrifuged at 800 g and 30,000 g, respectively,
to remove cell debris and microsomes. The supernatant was
centrifuged at 250,000 g to pellet the MV followed by resuspension
in TBS (pH 7.6) with 0.25mol/l sucrose. The MV amount was
determined by protein concentration (Bio-Rad).
Calcium deposition
After incubation in calcification or control media (with and without
b-glycerophosphate), BVSMCs were decalcified with 0.6N HCl for
24 h. The calcium content of HCl supernatants was determined
colorimetrically by the o-cresolphthalein complex one method
(Calcium kit; Pointe Scientific, Canton, MI, USA) and normalized
to protein content as previously described.28
Alkaline phosphatase activity
Alkaline phosphatase activity was measured using p-nitrophenyl
substrate supplied in an alkaline phosphatase assay kit (Pointe
Scientific) and normalized by protein content.28
MV-collagen calcification assay
MV-collagen calcification was determined as we previously des-
cribed.5 Briefly, glass coverslips were coated with type I collagen
(Sigma) in a 0.01% solution in 0.1mol/l acetic acid at room
temperature for 4 h, which yields approximately 8–10 mg/cm2
coating. Matrix vesicles isolated as above were added in equal
concentrations (10 mg per dish) to type I collagen-coated coverslips
in the presence of calcification media (DMEM with 15% FBS and
10mmol/l b-glycerophosphate) to yield an acellular MV-collagen
culture and incubated at 37 1C for 72 h. To determine the magnitude
of calcification of this MV-collagen culture, the media were removed
and the MV–ECM complex on the coverslips incubated in 0.6N HCl
for 24 h. The calcium content of HCL supernatants was determined
colorimetrically by the o-cresolphthalein complex one method
(Calcium kit; Pointe Scientific).
Organ culture
Segments of rat thoracic aorta measuring 3 cm were harvested from
male Sprague–Dawley rats and gently cleared of surrounding tissues.
Aortic segments were incubated in DMEM (Gibco, Long Island, NY,
USA) containing 1X penicillin/streptomycin and without serum at
37 1C in a humidified 5% CO2/95% air atmosphere. To induce
calcification, 7.5 units/ml of calf intestinal alkaline phosphatase was
added to DMEM and the phosphate ion concentration was
increased to 3.8mmol/l by the addition of sodium phosphate
(calcification medium) as per the methods of O’Neil and
colleagues.29 Verapamil or nifedipine (10, 20 and 50 mmol/l) was
pre-equilibrated in medium and then added to the culture medium.
Culture medium was changed every 2–3 days. After 7 days, aortic
specimens were rinsed in normal saline, minced, and decalcified in
300 ml of 0.6N HCL for 72 h with gentle agitation. The calcium
content of HCL supernatants was determined colorimetrically as
described above and normalized by tissue weight. Viability of aorta
organ cultures was determined by lactic dehydrogenase secretion
into the medium using CytoTox-One Homogeneous Membrane
Integrity Assay (Promega, Madison, WI, USA). When incubated
with 50 mmol/l verapamil or nifedipine, there was a marked increase
in lactic dehydrogenase indicating decreased viability of organ
cultures, and therefore we only evaluated results with 0, 10, or
20 mmol/l verapamil or nifedipine.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This work was supported by a K01 grant from the National Institutes
of Health/National Institute of Diabetes and Digestive and Kidney
Diseases (NIH/NIDDK) (NXC) and a VA Merit Award (SMM). We thank
Michelle Murray for her excellent secretarial assistance. The sources
of support were NIH/NIDDK and VA Merit Award.
REFERENCES
1. Anderson HC. Mechanisms of pathologic calcification. Rheumatic Diseases
Clinics of North America 1988; 14: 303–319.
2. Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep 2003;
5: 222–226.
3. Wang W, Xu J, Kirsch T. Annexin-mediated Ca2+ influx regulates growth
plate chondrocyte maturation and apoptosis. J Biol Chem 2003; 278:
3762–3769.
4. Kirsch T, Wang W, Pfander D. Functional differences between growth
plate apoptotic bodies and matrix vesicles. J Bone Miner Res 2003; 18:
1872–1881.
5. Chen NX, O0Neill KD, Chen X et al. Annexin-mediated matrix vesicle
calcification in vascular smooth muscle cells. J Bone Miner Res 2008; 23:
1798–1805.
6. Hughes AD. Calcium channels in vascular smooth muscle cells. J Vasc Res
1995; 32: 353–370.
7. Gollasch M, Haase H, Ried C et al. L-type calcium channel expression
depends on the differentiated state of vascular smooth muscle cells.
FASEB J 1998; 12: 593–601.
8. Valdivia HH, Valdivia C, Ma J et al. Direct binding of verapamil to the
ryanodine receptor channel of sarcoplasmic reticulum. Biophys J 1990; 58:
471–481.
9. Hernandez RH, Armas-Hernandez MJ, Velasco M et al. Calcium antagonists
and atherosclerosis protection in hypertension. Am J Ther 2003; 10: 409–414.
10. Motro M, Shemesh J, Grossman E. Coronary benefits of calcium
antagonist therapy for patients with hypertension. Curr Opin Cardiol
2001; 16: 349–355.
Kidney International (2010) 77, 436–442 441
NX Chen et al.: L-type calcium channel and vascular calcification o r ig ina l a r t i c l e
11. Motro M, Shemesh J. Calcium channel blocker nifedipine slows down
progression of coronary calcification in hypertensive patients compared
with diuretics. Hypertension 2001; 37: 1410–1413.
12. Essalihi R, Zandvliet ML, Moreau S et al. Distinct effects of amlodipine
treatment on vascular elastocalcinosis and stiffness in a rat model of
isolated systolic hypertension. J Hypertens 2007; 25: 1879–1886.
13. Schraven E, Trottnow D, Nitz RE. Inhibition of vitamin D3-induced
vascular calcification by carbocromen. Adv Myocardiol 1983; 4: 263–267.
14. Trion A, Schutte-Bart C, Bax WH et al. Modulation of calcification of
vascular smooth muscle cells in culture by calcium antagonists, statins,
and their combination. Mol Cell Biochem 2008; 308: 25–33.
15. Moe SM, Duan D, Doehle BP et al. Uremia induces the osteoblast
differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63:
1003–1011.
16. Moe SM, O’Neill KD, Duan D et al. Medial artery calcification in ESRD
patients is associated with deposition of bone matrix proteins. Kidney Int
2002; 61: 638–647.
17. Daut J, Standen NB, Nelson MT. The role of the membrane potential of
endothelial and smooth muscle cells in the regulation of coronary blood
flow. J Cardiovasc Electrophysiol 1994; 5: 154–181.
18. Gollasch M, Ried C, Bychkov R et al. K+ currents in human coronary artery
vascular smooth muscle cells. Circ Res 1996; 78: 676–688.
19. Haller H, Lindschau C, Quass P et al. Differentiation of vascular smooth muscle
cells and the regulation of protein kinase C-alpha. Circ Res 1995; 76: 21–29.
20. Franzini-Armstrong C, Protasi F. Ryanodine receptors of striated muscles:
a complex channel capable of multiple interactions. Physiol Rev 1997; 77:
699–729.
21. Balica M, Bostrom K, Shin V et al. Calcifying subpopulation of bovine
aortic smooth muscle cells is responsive to 17 beta-estradiol. Circulation
1997; 95: 1954–1960.
22. Bin G, Fen QY, Hua LX et al. Dysfunction of myocardial sarcoplasmic
reticulum in rats with myocardial calcification. Life Sci 2005; 77:
966–979.
23. Anderson HC, Garimella R, Tague SE. The role of matrix vesicles in
growth plate development and biomineralization. Front Biosci 2005; 10:
822–837.
24. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to
membrane dynamics. Nat Rev Mol Cell Biol 2005; 6: 449–461.
25. Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers
bind specifically to multidrug-resistant human KB carcinoma membrane
vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987;
262: 2166–2170.
26. Canaves JM, Ferragut JA, Gonzalez-Ros JM. Verapamil prevents the effects
of daunomycin on the thermotropic phase transition of model lipid
bilayers. Biochem J 1991; 279(Part 2): 413–418.
27. Pohl EE, Krylov AV, Block M et al. Changes of the membrane potential
profile induced by verapamil and propranolol. Biochem Biophys Acta
1998; 1373: 170–178.
28. Chen NX, O0Neill KD, Duan D et al. Phosphorus and uremic serum up-
regulate osteopontin expression in vascular smooth muscle cells. Kidney
Int 2002; 62: 1724–1731.
29. Lomashvili KA, Cobbs S, Hennigar RA et al. Phosphate-induced vascular
calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol
2004; 15: 1392–1401.
442 Kidney International (2010) 77, 436–442
or ig ina l a r t i c l e NX Chen et al.: L-type calcium channel and vascular calcification
